Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.

In some aspects, disclosed herein are methods and compositions for treatment or prevention of cerebral palsy using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neurogenesis and/or reducing inflammation in a subject. In some cases, the disclosed methods comprise use of conditioned fibroblasts. Fibroblasts may be conditioned with agents capable of enhancing therapeutic efficacy, for example oxytocin and/or human chorionic gonadotrophin (hCG).

In some aspects, disclosed herein are methods and compositions for treatment or prevention of cerebral palsy using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neurogenesis and/or reducing inflammation in a subject. In some cases, the disclosed methods comprise use of conditioned fibroblasts. Fibroblasts may be conditioned with agents capable of enhancing therapeutic efficacy, for example oxytocin and/or human chorionic gonadotrophin (hCG).

The problem that differences among lots in components and amounts of growth factors and the like in platelet-rich plasmas derived from an autologous plasma and the freeze-dried preparations thereof are large, and the effects of the lots are not kept constant is solved.

Specifically, a freeze-dried preparation comprising megakaryocytes and platelets induced to differentiate from stem cells, a pharmaceutical composition comprising the freeze-dried preparation, and the like are provided.

Coated bone grafts are provided as well as methods of use thereof and methods of making. In accordance with the instant invention, methods of preparing a coated bone graft (e.g., bone allograft) are provided. In certain embodiments, the method comprises electrospraying a composition comprising a polymer and, optionally, an agent, particularly a therapeutic agent, onto the surface of the bone graft. Therapeutic agents include, without limitation: bone stimulating agents, anti-fibrotic agents, antimicrobials, anti-inflammatory agents, and pro-angiogenesis agents.

The present disclosure generally relates to the field of infertility, and in particular male infertility. Accordingly, the present disclosure provides for compositions and methods for managing male infertility, caused by poor semen quality. More particularly, the present disclosure provides a therapeutic composition comprising a platelet rich plasma (PRP) or a growth factor concentrate derived therefrom and a thermoresponsive polymer. The present disclosure also relates to the compositions of PRP and the concentrate themselves. Consequently, methods to obtain the said compositions, along with therapeutic applications for treatment of infertility caused by poor semen quality are also provided.

This invention relates to methods of increasing the sensitivity of tumors to anti cancer therapies including antibody therapy, chemotherapy, radiotherapy, and therapies targeting cell signaling pathways such as the MAPK and PI3K pathways and receptor tyrosine kinases (e.g. EGFR). By increasing sensitivity of tumors to these agents, this invention will: (a)Prolong response in already responsive subjects; (b) Increase response rates by converting non-responsive patients into responsive patients; (c) Reverse treatment-induced resistance of tumors to anticancer therapy; and (d) Decrease treatment-associated toxicities by decreasing therapy dosages required for response. The invention also describes predictive tests, to identify patients most likely to respond to the combination treatments.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.

A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.